Predict your next investment

Ribon Therapeutics company logo
HEALTHCARE | Biotechnology
ribontx.com

See what CB Insights has to offer

Founded Year

2015

Stage

Series C | Alive

Total Raised

$163.5M

Last Raised

$65M | 6 mos ago

About Ribon Therapeutics

Ribon Therapeutics specializes in the development and discovery of monoPARP (mono ADP-ribose polymerase) inhibitors to block cancer cells' fundamental ability to survive under stress.

Ribon Therapeutics Headquarter Location

35 Cambridgepark Drive

Cambridge, Massachusetts, 02140,

United States

617-914-8700

Latest Ribon Therapeutics News

GRO Biosciences Strengthens Management Team With Appointment of Veteran Biotechnology Executive, Edward Stewart as Chief Business Officer

Nov 16, 2021

November 16, 2021 06:55 AM Eastern Standard Time BOSTON--( BUSINESS WIRE )-- GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the hiring of veteran industry executive, Edward “Tad” Stewart , who joins the team as Chief Business Officer (CBO). Mr. Stewart has worked extensively in business and corporate development in the biotechnology and pharmaceutical space for more than 20 years. He has played an integral strategic role in scaling platform biotechnology companies from early stages through FDA-approval and product launch. Mr. Stewart served most recently as Chief Business Officer of Ribon Therapeutics. Prior to his role at Ribon he served as President and CEO of Commense, Inc., Chief Business Officer of Crescendo Biologics, and spent many years with Merrimack Pharmaceuticals in various roles, including SVP of Business Development and Head of Commercial. Mr. Stewart received his MBA from Cornell University. “We are thrilled to have Tad join our executive team. His deep experience in business development and transactions will be instrumental to our partnering activities, and his expertise in product development will accelerate our commercialization efforts,” said Daniel J. Mandell, PhD, Co-Founder and Chief Executive Officer of GRO Biosciences. “Tad is an established leader in biotechnology, and his unique combination of transactional and strategic savvy will be a great asset to GRObio as we continue to advance our platform and pipeline.” About GRO Biosciences GRO Biosciences (“GRObio”) is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The Company is transforming treatments for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries. The Company’s NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system. GRObio, co-founded by George Church, PhD of Harvard Medical School in 2016, is headquartered in Cambridge, MA. Find GRObio on LinkedIn , Twitter , Instagram , Facebook and the web at grobio.com . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ribon Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ribon Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

818 items

Ribon Therapeutics Patents

Ribon Therapeutics has filed 3 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Cell biology
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/11/2020

5/25/2021

Transcription factors, Proteins, Human proteins, Clusters of differentiation, Cell biology

Grant

Application Date

8/11/2020

Grant Date

5/25/2021

Title

Related Topics

Transcription factors, Proteins, Human proteins, Clusters of differentiation, Cell biology

Status

Grant

Ribon Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ribon Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.